Aspen Investment Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.02M Buy
3,349
+100
+3% +$102K 1.08% 23
2026
Q1
$2.99M Buy
3,249
+94
+3% +$95.3K 0.92% 25
2025
Q4
$3.39M Buy
3,155
+1,888
+149% +$1.81M 1.02% 22
2025
Q3
$967K Buy
1,267
+250
+25% +$186K 0.37% 73
2025
Q2
$793K Buy
1,017
+44
+5% +$34.2K 0.33% 77
2025
Q1
$804K Buy
973
+46
+5% +$38.3K 0.37% 77
2024
Q4
$716K Sell
927
-257
-22% -$213K 0.33% 77
2024
Q3
$1.05M Buy
1,184
+73
+7% +$65.6K 0.49% 59
2024
Q2
$1.01M Buy
1,111
+9
+0.8% +$7.2K 0.5% 58
2024
Q1
$857K Buy
1,102
+18
+2% +$12.8K 0.44% 69
2023
Q4
$632K Buy
1,084
+493
+83% +$288K 0.35% 79
2023
Q3
$317K Buy
+591
New +$305K 0.19% 114
2023
Q1
Sell
-692
Closed -$253K 136
2022
Q4
$253K Sell
692
-14
-2% -$4.96K 0.17% 111
2022
Q3
$228K Buy
+706
New +$224K 0.15% 124
2020
Q4
Sell
-2,138
Closed -$316K 136
2020
Q3
$316K Buy
2,138
+111
+5% +$17.2K 0.21% 96
2020
Q2
$333K Buy
+2,027
New +$311K 0.24% 92

Other funds holding LLY

Aspen Investment Management's LLY Position: Q2 2026 in Review

Aspen Investment Management increased its Eli Lilly (LLY) stake by 3.1% in Q2 2026, buying an estimated $102K and bringing the position to 3,349 shares worth $4.02M. The position accounts for 1.08% of the portfolio, ranked #23.

Aspen Investment Management first reported a position in LLY in Q2 2020 and has held it in 16 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Aspen Investment Management held 3,349 shares of Eli Lilly worth $4.02M as of Q2 2026.
  • Aspen Investment Management bought 100 Eli Lilly shares in Q2 2026, an estimated $102K.
  • Eli Lilly made up 1.08% of Aspen Investment Management's portfolio in Q2 2026, its #23 holding.
  • Aspen Investment Management first reported a position in Eli Lilly in Q2 2020 and has held it in 16 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Aspen Investment Management's 13F filing for Q2 2026, filed 17 Jul 2026.